



ABN 53 075 582 740

ASX ANNOUNCEMENT

1 September 2017

Bionomics BNC210 to Feature at the 30th ECNP Congress

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, has announced that a Brainstorming Session will be held at the 30th ECNP congress in Paris on the topic of the $\alpha 7$ nicotinic acetylcholine receptor ($\alpha 7$ nAChR) negative allosteric modulators as next generation anxiolytics. BNC210 will feature in the session as it is the first clinical example of an anxiolytic small molecule drug with this mechanism of action.

The Brainstorming Session will be held on Sunday September 3rd at 7.45 am and will be chaired by Dr Judith Homberg from the Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, The Netherlands.

Experts leading the discussion will be Jens Mikkelsen, MD, DMSc, Professor in Translational Neuropharmacology, University of Copenhagen, Denmark and Christopher Lowry Ph.D. from the Department of Integrative Physiology, University of Colorado, USA.

The anxiolytic activity of BNC210 has been demonstrated in a Phase II clinical trial in patients with Generalised Anxiety Disorder (GAD). Unlike the standard of care treatments for anxiety, BNC210 is not sedating, does not impair memory or motor co-ordination and shown no evidence of causing addiction. BNC210 is currently in a Phase II clinical trial for the treatment of Post-Traumatic Stress Disorder (PTSD). Enrolment is ongoing in this trial at sites across Australia and the US.

FOR FURTHER INFORMATION PLEASE CONTACT:

Australia

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US

Stern Investor Relations
Beth DelGiaccio
+1 212 362 1200
beth@sternir.com

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, a humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au

About ECNP and the Congress

ECNP is an independent scientific association dedicated to the science and treatment of disorders of the brain. It is the largest non-institutional supporter of applied and translational neuroscience research and education in Europe. The ECNP Congress is Europe's largest meeting on applied and translational neuroscience. Annually it brings together approximately 6,000 psychiatrists, neuroscientists, neurologists and psychologists from around the world to discuss the latest developments in the science and treatment of disorders of the brain. The ECNP Congress is Europe's premier showcase for new research, treatments and technologies in applied brain science, spanning the spectrum of human mood, behaviour, cognition and emotion, from basic science to clinical care.

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.